Shots:

• The P-III CHIASMA OPTIMAL study involves assessing of Mycapssa formulated as capsules vs PBO in 56 patients in a ratio (1:1) with acromegaly prior treated with somatostatin analogs for 9mos.- conducted under a SPA agreement with FDA
• The P-III CHIASMA OPTIMAL study results: met its 1EPs & 2EPs; maintained IGF-1 response (58% vs 19%); maintained GH level below 2.5 ng/mL (78% vs 30%); requirement of rescue medication (25% vs 68%); safe & well tolerated
•  Mycapssa is an oral formulation of the somatostatin analog octreotide- currently in development for the treatment of acromegaly with its expected NDA submission for octreotide capsules in H2’19

Click here to read full press release/ article | Ref: Chiasma | Image: Chiasma